Skip to main content
Log in

Reimbursements decrease after approval of insulin biosimilar

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Reference

  • Hernandez I, et al. Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018. JAMA: the Journal of the American Medical Association : 25 Mar 2019. Available from: URL: http://doi.org/10.1001/jama.2019.2990

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reimbursements decrease after approval of insulin biosimilar. PharmacoEcon Outcomes News 825, 27 (2019). https://doi.org/10.1007/s40274-019-5793-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5793-x

Navigation